[HTML][HTML] Efficacy and safety of rovalpituzumab tesirine compared with topotecan as second-line therapy in DLL3-high SCLC: results from the phase 3 TAHOE study
F Blackhall, K Jao, L Greillier, BC Cho, K Penkov… - Journal of Thoracic …, 2021 - Elsevier
Introduction DLL3, an atypical Notch ligand, is expressed in SCLC tumors but is not
detectable in normal adult tissues. Rovalpituzumab tesirine (Rova-T) is an antibody-drug …
detectable in normal adult tissues. Rovalpituzumab tesirine (Rova-T) is an antibody-drug …
Anlotinib vs placebo as third-or further-line treatment for patients with small cell lung cancer: a randomised, double-blind, placebo-controlled Phase 2 study
Y Cheng, Q Wang, K Li, J Shi, Y Liu, L Wu… - British Journal of …, 2021 - nature.com
Background This study aimed to evaluate the efficacy and safety of anlotinib as a third-line
and subsequent treatment for patients with small cell lung cancer (SCLC). Methods We …
and subsequent treatment for patients with small cell lung cancer (SCLC). Methods We …
[HTML][HTML] Camrelizumab plus apatinib in extensive-stage SCLC (PASSION): a multicenter, two-stage, phase 2 trial
Y Fan, J Zhao, Q Wang, D Huang, X Li, J Chen… - Journal of Thoracic …, 2021 - Elsevier
Introduction Treatment options in the second-line extensive-stage SCLC (ED-SCLC) setting
are limited. The PASSION study (ClinicalTrials. gov identifier: NCT03417895) was a phase 2 …
are limited. The PASSION study (ClinicalTrials. gov identifier: NCT03417895) was a phase 2 …
Exploratory composite endpoint demonstrates benefit of trilaciclib across multiple clinically meaningful components of myeloprotection in patients with small cell lung …
M Dómine Gómez, T Csőszi, J Jaal… - … Journal of Cancer, 2021 - Wiley Online Library
Chemotherapy‐induced myelosuppression is an acute, dose‐limiting toxicity of
chemotherapy regimens used in the treatment of extensive‐stage small cell lung cancer (ES …
chemotherapy regimens used in the treatment of extensive‐stage small cell lung cancer (ES …
[HTML][HTML] Toxicities of immunotherapy for small cell lung cancer
Y Fu, Y Zheng, PP Wang, ZY Ding - Frontiers in Oncology, 2021 - frontiersin.org
Small cell lung cancer (SCLC), composing 15–20% of lung cancer, is a fatal disease with
extremely poor prognosis. In the past two decades, etoposide platinum doublet …
extremely poor prognosis. In the past two decades, etoposide platinum doublet …
Results from a biomarker study to accompany a phase II trial of RRx-001 with reintroduced platinum-based chemotherapy in relapsed small cell carcinoma
MJ Lee, Y Tomita, A Yuno, S Lee… - Expert opinion on …, 2021 - Taylor & Francis
ABSTRACT Background: In a Phase II study RRx-001 was combined with Etoposide
platinum (EP) in previously platinum treated SCLC. We correlated expression of the M2 …
platinum (EP) in previously platinum treated SCLC. We correlated expression of the M2 …
Clinical activity and safety of anlotinib combined with PD-1 blockades for patients with previously treated small cell lung cancer
YY Hao, YP Qiao, JD Cheng - International Journal of General …, 2021 - Taylor & Francis
Objective Anlotinib was the standard monotherapy for patients with previously treated small
cell lung cancer (SCLC) in recent years. Programmed cell death protein 1 (PD-1) blockade …
cell lung cancer (SCLC) in recent years. Programmed cell death protein 1 (PD-1) blockade …
[HTML][HTML] Exploring the antivirulence activity of pulverulentone A, a phloroglucinol-derivative from Callistemon citrinus leaf extract, against multi-drug resistant …
(1) Background: Bacterial resistance to antibiotics is a global life-threatening issue.
Antivirulence therapy is a promising approach to combat bacterial infections as it disarms …
Antivirulence therapy is a promising approach to combat bacterial infections as it disarms …
小细胞肺癌治疗新进展
张爽， 程颖 - 中国肿瘤临床, 2021 - cjco.cn
小细胞肺癌(small cell lung cancer, SCLC) 治疗进展缓慢, 依托泊苷联合铂类和拓扑替康作为
SCLC 一线和二线治疗选择已经延续30 余年, 三线及以上SCLC 一直没有标准治疗方案. 因此 …
SCLC 一线和二线治疗选择已经延续30 余年, 三线及以上SCLC 一直没有标准治疗方案. 因此 …
Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
E Bayever, N Dhindsa, JB Fitzgerald, P Laivins… - US Patent …, 2021 - Google Patents
(57) ABSTRACT Int. Cl. A61K 31/4745(2006.01) A61K 9/00(2006.01) A61K 9/127(2006.01)
A61K 31/513(2006.01) A61K 31/517(2006.01) A61K 31/519(2006.01) A61K …
A61K 31/513(2006.01) A61K 31/517(2006.01) A61K 31/519(2006.01) A61K …